Liang Li

Liang Li

National Center for Toxicological Research - - / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4401224
-
person_outline Liang Li's MOST POPULAR ARTICLES
1-) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndromeRQ Le, L Li, W Yuan, SS Shord, L Nie, BA Habtemariam, D Przepiorka, ...The oncologist 23 (8), 943-947, 20186262018
2-) FDA Approval Summary:(Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid LeukemiaFDA Approval:(Daunorubicin and …AC Krauss, X Gao, L Li, ML Manning, P Patel, W Fu, KG Janoria, G Gieser, ...Clinical Cancer Research 25 (9), 2685-2690, 20191942019
3-) FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmFDA Approval Summary: Tagraxofusp-erzsEY Jen, X Gao, L Li, L Zhuang, NE Simpson, B Aryal, R Wang, ...Clinical Cancer Research 26 (3), 532-536, 2020642020
4-) A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patientsY Lu, Q Su, K Wu, Y Ren, L Li, T Zhou, W LuActa Pharmacologica Sinica 36 (2), 281-288, 2015532015
5-) Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cellsS Wang, Z Mou, Y Ma, J Li, J Li, X Ji, K Wu, L Li, W Lu, T ZhouBiochemical pharmacology 95 (2), 98-109, 2015522015